A Plasmidic Class 1 Integron from Five Pseudomonas aeruginosa Clinical Strains Harbored aacA4 and Nonsense-mutated cmlA1 Gene Cassettes

DOI Web Site Web Site 参考文献40件
  • Yan He
    College of Light Industry and Food Technology, South China University of Technology
  • Shi Lei
    College of Light Industry and Food Technology, South China University of Technology
  • Yamasaki Shinji
    College of Light Industry and Food Technology, South China University of Technology Osaka Prefecture University
  • Li Xinhui
    School of Biological Science and Bioengineering, South China University of Technology
  • Cao Yicheng
    School of Biological Science and Bioengineering, South China University of Technology
  • Li Lin
    College of Light Industry and Food Technology, South China University of Technology
  • Yang Liansheng
    College of Light Industry and Food Technology, South China University of Technology
  • Miyoshi Shin-ichi
    Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

この論文をさがす

抄録

Five strains of multidrug-resistant Pseudomonas aeruginosa (P. aeruginosa) were isolated from inpatients at a local hospital in China. The most frequent resistance was to cefoperazone, ciprofloxacin, ceftriaxone, cefotaxime, gentamicin, piperacillin, trimethoprim sulfamethoxazole, and tobramycin. These strains were found to contain the class 1 integron, in which the 2360-bp gene cassettes were flanked by 5'- and 3'-conserved segments. Sequence analysis revealed that the gene cassettes contained aacA4 and cmlA1 genes; however, the latter gene had a nonsense mutation resulting in the production of a truncated protein. To the best of our knowledge, this is the first report of a nonsense mutation in the cmlA1 gene. Moreover, the P. aeruginosa strains showed identical profiles in pulsed-field gel electrophoresis, suggesting that they were derived from the same clone. These results emphasize the importance of controlling the spread of multidrug-resistant pathogens in hospitals.

収録刊行物

参考文献 (40)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ